Latest Oncology News

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Latest Oncology Videos

All Oncology News

Hormone Therapies, ADCs Elicit Long-Term Survival Benefits Across Breast Cancer Subtypes

June 17th 2022

Ashling Wahner

Novel combinations with CDK4/6 inhibitors, antibody-drug conjugates, and oral selective estrogen receptor degraders are rapidly changing the treatment paradigm in hormone receptor–positive and HER2-positive breast cancer.

Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

June 17th 2022

Daniel Pollyea, MD, MS

A review of treatment options for patients with newly diagnosed acute myeloid leukemia and differences between patients who are fit vs unfit for chemotherapy.

Dr. George on the Background of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 16th 2022

Mridula George, MD

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

Importance of Molecular Testing in Acute Myeloid Leukemia to Guide Treatment

June 16th 2022

Richard M. Stone, MD

Richard Stone, MD, and Eunice Wang, MD, explain how molecular biomarker testing influences their treatment decision-making in patients with acute myeloid leukemia (AML).

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

June 16th 2022

Kristi Rosa

The peptide cancer vaccine onilcamotide failed to show superiority over placebo in terms of preventing progression in patients with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.

Patient Profile 2: Patient with de novo AML and IDH2 Mutation

June 16th 2022

Richard M. Stone, MD

Drs Richard Stone and Eunice Wang review the clinical profile of a 67-year-old man with newly diagnosed acute myeloid leukemia (AML) and an IDH2 mutation.

Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC

June 16th 2022

Robert S. Alter, MD

Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.

Navitoclax Monotherapy Mirrors Safety of Navitoclax/Ruxolitinib, But Falls Short in Efficacy in Myelofibrosis

June 16th 2022

Chris Ryan

Single-agent navitoclax achieved a manageable safety profile compared with navitoclax plus ruxolitinib in patients with myelofibrosis. However, efficacy results, specifically at 24 weeks of treatment, favored the combination over navitoclax monotherapy.

Lee Lays Out Treatment Developments in Non–Clear Cell RCC

June 16th 2022

OncLive Staff

Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.

Advanced RCC Patient Referrals from Community Oncologists

June 16th 2022

Robert S. Alter, MD

Elan Diamond, MD, describes when and how often community oncologists refer patients with suspected advanced renal cell carcinoma to his practice.

FDA Grants Fast Track Status to PDS0101/Pembrolizumab Combo for Recurrent or Metastatic, HPV16+ Head and Neck Cancer

June 16th 2022

Kristi Rosa

The FDA has granted a fast track designation to PDS0101 for use in combination with pembrolizumab in patients with recurrent or metastatic HPV16-positive head and neck cancer.

Dr. Llanos on Recognizing Social Determinants of Disparities in Cancer Care

June 16th 2022

Adana A.M. Llanos, PhD, MPH

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients

June 16th 2022

Rutgers Cancer Institute of New Jersey

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

Cosibelimab Continues to Show Promise in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 16th 2022

Kristi Rosa

The PD-L1 antibody cosibelimab was found to elicit an encouraging objective response rate in patients with locally advanced cutaneous squamous cell carcinoma who were not eligible to undergo curative surgery or radiation.

Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers

June 16th 2022

Suneel Kamath, MD

Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.

See All News